Airhart SE, Shireman LM, Risler LJ, et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One 2017;12(12):e0186459. View abstract.
Braidy N, Berg J, Clement J, et al. Role of nicotinamide dinucleotide and related precursors as therapeutic targets for age-related degenerative diseases: rationale, biochemistry, pharmacokinetics, and outcomes. Antiox Redox Signal 2018. View abstract.
Brown KD, Maqsood S, Huang JY, et al. Activation of SIRT3 by the NAD? precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metab 2014;20(6):1059-68. View abstract.
Chi Y, Sauve AA. Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection. Curr Opin Clin Nutr Metab Care 2013;16(6):657-61. View abstract.
Close GL, Hamilton DL, Philp A, Burke LM, Morton JP. New strategies in sport nutrition to increase exercise performance. Free Radic Biol Med 2016;98:144-58. View abstract.
Conze D, Brenner C, Kruger CL. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep 2019;9(1):9772. View abstract.
Dellinger RW, Santos SR, Morris M, et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safety and sustainably: a randomized, double-blind, placebo-controlled study. NPJ J Aging Mech Dis 2017;3:17. View abstract.
Diguet N, Trammell SAJ, Tannous C, et al. Nicotinamide riboside preserves cardiac function in a mouse model of dilated cardiomyopathy. Circulation 2018;137(21):2256-73. Erratum in: Circulation 2018;137(21):e690. View abstract.
Dollerup OL, Christensen B, Svart M, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr 2018;108(2):343-53. View abstract.
Dollerup OL, Chubanava S, Agerholm M, et al. Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin resistant men. J Physiol 2019 [Epub ahead of print]. View abstract.
Dollerup OL, Trammell SAJ, Hartmann B, et al. Effects of nicotinamide riboside on endocrine pancreatic function and incretin hormones in nondiabetic men with obesity. J Clin Endocrinol Metab 2019;104(11):5703-14. View abstract.
Dolopikou CF, Kourtzidis IA, Margaritelis NV, et al. Acute nicotinamide riboside supplementation improves redox homeostasis and exercise performance in old individuals: a double-blind cross-over study. Eur J Nutr 2019 [Epub ahead of print]. View abstract.
Elhassan YS, Philp AA, Lavery GG. Targeting NAD+ in metabolic disease: new insights into an old molecule. J Endocr Soc 2017;1(7):816-35. View abstract.
Gong B, Pan Y, Vemati P, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-? coactivator 1a regulated ß-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Nuerobiol Aging 2013;34(6):1581-8. View abstract.
Han X, Bao X, Lou Q, et al. Nicotinamide riboside exerts protective effect against aging-induced NAFLD-like hepatic dysfunction in mice. PeerJ 2019;7:e7568. View abstract.
Hong G, Zheng D, Zhang L, et al. Administration of nicotinamide riboside prevents oxidative stress and organ injury in sepsis. Free Radic Biol Med 2018;123:125-37. View abstract.
Johnson S, Imai SI. NAD+ biosynthesis, aging, and disease. F1000Res 2018;7:132. View abstract.
Lee HJ, Yang SJ. Supplementation with nicotinamide riboside reduces brain inflammation and improves cognitive function in diabetic mice. Int J Mol Sci 2019;20(17). pii: E4196. View abstract.
Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun 2018;9(1):1286. View abstract.
Remie CME, Roumans KHM, Moonen MPB, et al. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. Am J Clin Nutr. 2020;112(2):413-426. View abstract.
Shi W, Hegeman MA, Doncheva A, Bekkenkamp-Grovenstein M, de Boer VCJ, Keijer J. High dose of dietary nicotinamide riboside induces glucose intolerance and white adipose tissue dysfunction in mice fed a mildly obesogenic diet. Nutrients 2019;11(10). pii: E2439. View abstract.
Stocks B, Ashcroft SP, Joanisse S, et al. Nicotinamide riboside supplementation does not alter whole-body or skeletal muscle metabolic responses to a single bout of endurance exercise. J Physiol. 2021. View abstract.
Teijeiro A, Djouder N. Nicotinamide riboside or IL-17A signaling blockers to prevent liver disorders. Oncoscience 2017;4(1-2):1-2. View abstract.
Trammell SA, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun 2016;7:12948. View abstract.
Trammell SA, Yu L, Redpath P, Migaud ME, Brenner C. Nicotinamide riboside is a major NAD+ precursor vitamin in cow milk. J Nutr 2016;146(5):957-63. View abstract.
Turck D, Castenmiller J, de Henauw S, et al. Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC. EFSA J. 2019;17(8):e05775. View abstract.
Xie X, Gao Y, Zeng M, et al. Nicotinamide ribose ameliorates cognitive impairment of aged and Alzheimer's disease model mice. Metab Brain Dis 2019;34(1):353-66. View abstract.
Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab 2018;27(3):513-28. View abstract.
Zhang X, Henneman NF, Girardot PE, Sellers JT, Chrenek MA, Li Y, Wang J, Brenner C, Nickerson JM, Boatright JH. Systemic Treatment With Nicotinamide Riboside Is Protective in a Mouse Model of Light-Induced Retinal Degeneration. Invest Ophthalmol Vis Sci. 2020;61(10):47. View abstract.